Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study.
Patrikidou A, Saieva C, Lee-Ying R, Nuzzo PV, Zarif TE, McClure H, Davidsohn M, Eid M, Spinelli GP, Catalano F, Cremante M, Fotia G, Rossetti S, Valenca L, Vauchier C, Ottanelli C, Andrade L, Gennusa V, Mestre RP, Fornarini G, Pignata S, Procopio G, Santini D, Ravi P, Sweeney C, Heng D, De Giorgi U, Fizazi K, Russo A, Francini E; SPARTACUSS Group. Patrikidou A, et al. Among authors: pignata s. Clin Genitourin Cancer. 2024 Oct 5;22(6):102230. doi: 10.1016/j.clgc.2024.102230. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39461026 Free article.
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valenca Bueno L, Andrade LMQS, Patrikidou A, Mestre RP, Modesti M, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E; SPARTACUSS Investigators. Nuzzo PV, et al. Among authors: pignata s. J Transl Med. 2023 Feb 3;21(1):75. doi: 10.1186/s12967-022-03861-2. J Transl Med. 2023. PMID: 36737752 Free PMC article.
Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Nuzzo PV, Ravera F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valença LB, Oliveira TM, Vauchier C, Pereira Mestre R, Modesti M, Patrikidou A, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E. Nuzzo PV, et al. Among authors: pignata s. Ther Adv Med Oncol. 2023 Mar 3;15:17588359231156147. doi: 10.1177/17588359231156147. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36895852 Free PMC article.
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study.
Fotia G, Saieva C, Lee-Ying R, Patrikidou A, Nuzzo PV, Zanardi E, Rossetti S, Davidsohn M, Eid M, El Zarif T, McClure H, Spinelli GP, Damassi A, Murianni V, Vauchier C, Oliveira TM, Malgeri A, Modesti M, Mestre RP, Valenca L, Ravi P, Santini D, Pignata S, De Giorgi U, Sweeney C, Heng D, Procopio G, Russo A, Francini E; Spartacuss Group. Fotia G, et al. Among authors: pignata s. Clin Genitourin Cancer. 2024 Oct;22(5):102185. doi: 10.1016/j.clgc.2024.102185. Epub 2024 Aug 9. Clin Genitourin Cancer. 2024. PMID: 39217072 Free article.
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.
Raggi D, Giannatempo P, Marandino L, Pierantoni F, Maruzzo M, Lipari H, Banna GL, De Giorgi U, Casadei C, Naglieri E, Buti S, Bersanelli M, Stellato M, Santini D, Vignani F, Roviello G, Veccia A, Caffo O, Losanno T, Calabrò F, Mucciarini C, Pignata S, Necchi A, Maio MD; MEET-URO Group. Raggi D, et al. Among authors: pignata s. Clin Genitourin Cancer. 2022 Apr;20(2):155-164. doi: 10.1016/j.clgc.2021.12.008. Epub 2021 Dec 16. Clin Genitourin Cancer. 2022. PMID: 35000876
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Roviello G, Gambale E, Giorgione R, Santini D, Stellato M, Fornarini G, Rebuzzi SE, Basso U, Bimbatti D, Doni L, Nesi G, Bersanelli M, Buti S, De Giorgi U, Galli L, Sbrana A, Conca R, Carella C, Naglieri E, Pignata S, Procopio G, Antonuzzo L. Roviello G, et al. Among authors: pignata s. Cancer Med. 2022 Aug;11(16):3084-3092. doi: 10.1002/cam4.4681. Epub 2022 Mar 20. Cancer Med. 2022. PMID: 35312175 Free PMC article.
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
Santini D, Stellato M, De Giorgi U, Pantano F, De Lisi D, Casadei C, Maruzzo M, Bimbatti D, Naglieri E, Buti S, Bersanelli M, De Vivo R, Di Lorenzo G, Sbrana A, Verzoni E, Soraru' M, Fornarini G, Mucciarini C, Grillone F, Mini E, Vignani F, Attademo L, Pignata S, Procopio G. Santini D, et al. Among authors: pignata s. Am J Clin Oncol. 2021 Mar 1;44(3):121-125. doi: 10.1097/COC.0000000000000791. Am J Clin Oncol. 2021. PMID: 33617179
Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators.
Stellato M, Procopio G, De Giorgi U, Maruzzo M, Bimbatti D, Mennitto A, Sbrana A, Roviello G, Casadei C, Sepe P, Pignata S, Santini D. Stellato M, et al. Among authors: pignata s. J Transl Med. 2021 Aug 3;19(1):328. doi: 10.1186/s12967-021-03008-9. J Transl Med. 2021. PMID: 34344414 Free PMC article.
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
Bersanelli M, Buti S, Cortellini A, Bandini M, Banna GL, Pederzoli F, Farè E, Raggi D, Giannatempo P, De Giorgi U, Basso U, Losanno T, Santini D, Mucciarini C, Tucci M, Tambaro R, Farnesi A, Caffo O, Veccia A, Naglieri E, Briganti A, Procopio G, Pignata S, Necchi A. Bersanelli M, et al. Among authors: pignata s. Clin Med Insights Oncol. 2021 Jul 8;15:11795549211021667. doi: 10.1177/11795549211021667. eCollection 2021. Clin Med Insights Oncol. 2021. PMID: 34290538 Free PMC article.
471 results